Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups.
D000017:ABO Blood-Group System / Q000276:immunology; D000328:Adult; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D002648:Child; D003429:Cross Reactions; D006801:Humans; D007223:Infant; D008586:Meningitis, Pneumococcal / Q000382:microbiology; D009895:Opsonin Proteins; D010587:Phagocytosis; D011008:Pneumococcal Infections / Q000382:microbiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial / Q000145:classification / Q000276:immunology; D013045:Species Specificity; D013296:Streptococcus pneumoniae / Q000145:classification / Q000276:immunology*; D014611:Vaccination
D000017:ABO Blood-Group System; D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D009895:Opsonin Proteins; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial